1Miyazaki T, Yadome T, Siguira M, Ito, and Fujii K. Chemical structure of anti-tumour polysaccharide, coriolan, produced by Coriolus versicolor.
Chemical and Pharmaceutical Bulletin. 1974; 22: 1739-1742.
2Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K. Krestin (PSK).
Cancer treatment Reviews. 1984; 11:131-155.
3Ikuzawa M, Matsunaga K, Nishiyama S, Nakjima S, Kobayashi Y et al. Fate and distribution of an antitumour protein-bound polysaccharide PSK .
Int J Immunopharmacol. 1988; 10: 415-423.
4Yunoki S, Tanaka N, Hizuta A, Orita K. Enhancement of antitumour cytotoxicity of hepatic lymphocytes by oral administration of PSK.
Int J Immunopharmacol. 16:123-130, 1994.
5 Fujita H, Ogawa K, Ikuzawa M, Muto S et al. Effects of PSK on drug-metabolizing enzymes with special reference to the activation of FT-207.
Jap J Cancer and Immunotherapy. 1986; 13: 2653-2657.
6Kato M, Hirose K, Hakzaki M, Ohno M et al 1995. Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide.
Cancer Immunology Immunotherapy. 1995; 40: 152-156.
7Kikichi Y, Kizawa I, Oomori K, Iwano I, Kita T et al. Effects of cimetidine and PSK on interleukin 2 production by PBL in patients with advance ovarian carcinoma during the course of chemotherapy.
Acta Obst Gynaecologica Japnica. 1987; 39: 1987-1992.
8Yokoe Y, Kato H, Takemura S et al. Effect of long-term administration of OK-432 (Picibanil), PSK (Krestin) and levamisole on immune responses in aged subjects without malignancy.
Jap J Clin Oncol. 1979; 9(2): 209-214.
9Torisu M, Hayashi Y, Ishimitsu T, Fujimure T et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer.
Cancer Immunology Immunotherapy. 1990; 31: 261-268.
10Munro JA. The use of the medicinal mushroom Coriolus MRL as an immuno-therapeutic agent in the treatment of patients with chronic fatigue syndrome.
J Integrative Med. 2004: 8: 101-108.
11Toge T, Kegoya Y, Yamaguchi Y, Baba N et al. Surgical stress and immunosuppression in cancer patients.
Jap J Cancer Chemother..1989; 16: 1115-1121.
12Ogawa K, Hirai M, Katsube T, Kajiwara T. Surgical stress and lymphocyte function: effects of PSK to prevent cellular immunosuppression.
J Nippon Medical School. 1993; 60: 316-320.
13Kariya Y, Inoue N, Kihara T, Okamoto N, Sugie K et al. Activation of human natural killer cells by the protein-bound PSK independently of interferon and interleukin 2.
Immunology Letters. 1992; 31: 241-246.
14Mizutani Y, Yoshida O. Activation by the protein-bound polysaccharide PSK (Krestin) of cytotoxic lymphocytes that act on fresh autologous tumour cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer.
J Urol 1991; 145:1082-1087.
15Del Prete G. The concept of type-1 and type-2 helper T cells and their cytokines in humans.
Int Rev Immunol 1998; 16: 427-55.
16Kanazawa M, Yoshihara K, Abe H et al. Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients.
Anticancer Res. 2005; 25:443-450.
17Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K et al. Randomized, controlled study on adjuvant immunotherapy with PSK in curatively resected colorectal cancer.
Dis Colon Rectum. 1992; 35: 123-130.
18Ohwada S, Kawate S, Ikeya T, Yokomori T, Kusaba T et al. Adjuvant therapy with protein-bound polysaccharide K and tegafur/uracil in patients with Stage II or III colorectal cancer: Randomized, controlled trial.
Dis Colon Rectum. 2003; 46: 1060-1068.
19 Ohwada S, Ikeya T, Yokomori T, Kusab T, Roppongi T, et al. Adjuvant immunotherapy with oral tegafur/uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study.
British Journal of Cancer. 2004; 90: 1003-1010.
20Ito K, Nakazato H, Koike A et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7 year follow-up.
Int J Colorectal Dis. 2004; 19(2): 157-64.
21Sakamoto J, Morita S, Oba K, et al. Efficacy of adjuvant immunotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomised controlled clinical trials.
Cancer Immunol Immunother. 2006; 55:404-411.
22Hayakawa H, Mitsuibashi N, Saito Y, Takahashi M et al. Effect of Krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small lung cancer.
Anticancer Res. 1993; 13: 1815-1820.
23Toi M, Hattori, Akagi M et al. Randomised adjuvant trial to evaluate the addition of Tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organisation.
Cancer 1992; 70(10):2475-83.
24 Iino Y, Yokoe T, Maemura M, Horiguchi J, Takel H et al. Immunochemotherapies versus Chemotherapy as adjuvant treatment after curative resection of operable breast cancer.
Anticancer Res. 1995; 15: 2907-2912.
25Yokoe T, Iimo Y, Takei H, Horiguchi J et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunotherapy with PSK.
Anticancer Res. 1997; 17: 2815-2818.
26Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J, Efficacy of immunotherapy as adjuvant treatment after curative resection of gastric cancer Lancet 1994; 343: 1122-26.
27Ogoshi K, Miyaji M, Nakmura K, Kondoh Y, Makuuchi H, Tajima T. Immunotherapy and combined assay of serum levels of carcinoembryonic antigen and acute phase reactants.
Cancer Immunology Immunotherapy. 1998; 46: 14-20.
28Ogoshi K,Satou H, Isono K, Mitomi T Endoh M, Sugita M. Possible predictive markers of immunotherapy of oesophageal cancer: retrospective analysis of a randomised study. The Co-operative Study Group for Oesophageal Cancer in Japan.
Cancer Invest. 1995; 13: 363-369.
29Go P, Chung CH. Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx.
J Int Med Res. 1989; 17: 141-149.
30Ohno R, Yamada K, Masaoka T, Oshima T, Amaki I et al. 1984. A randomized trial of chemo immunotherapy of acute nonlymphocytic leukaemia in adults using a protein-bound polysaccharide preparation.
Cancer Immunology Immunotherapy1984; 18: 149-154.
31Kawa K, Konishi S, Tsujino G, Mabuchi S. Effects of biological response modifiers on childhood ALL being in remission after chemotherapy.
Biomedicine and Pharmacotherapy. 1991; 45: 113-116.
32Wong CK, Tse PS, Wong EL, Leung PC, Fung KP, Lam CW. Immunomodulatory effects of Yun Zhi and Danshen capsules in healthy subjects- a randomised, double-blind, placebo-controlled crossover study.
Int Immunopharmacol. 2004; 4: 201-11.
33Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, Collection of Information on Drug Adverse Reaction Report No. 48, Tokyo Ministry of Health and Welfare, 1980.
34Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment.
Altern. Med Rev 2000; 5: 4-27.
35American National Cancer Research Centre. Applied Microbiology. 1989; 34: 183-264.